ArticleNature protocols2019
CRISPR-Cas9 genome engineering of primary CD4
Abstract read
In one paragraph
Article in Nature protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 131 citations in OpenAlex.
- Article
- Combination treatment with synthetic gRNA/Cas12a and gRNA/Cas9 ribonucleoproteins disrupts HIV replication and expression.iScience · 2026Article
- microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2.Molecular therapy. Nucleic acids · 2026Article
- Suppression of HBV replication and expression by CRISPR/Cas9 ribonucleoproteins.Antiviral research · 2026Article
- HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing.Nature communications · 2025Article
- Alternative polyadenylation upon CPSF6 knock-out enhances HIV-1 infection in primary T cells.PLoS pathogens · 2025Article
- Single-base mJournal of virology · 2025Article
- Impact of NbioRxiv : the preprint server for biology · 2025Article
- Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection.PLoS biology · 2025Article
- CPSF6 promotes HIV-1 preintegration complex function.Journal of virology · 2025Article
- Ribosome customization and functional diversification among P-stalk proteins regulate late poxvirus protein synthesis.Cell reports · 2025Article
- Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review.International journal of nanomedicine · 2025Review
- Disruption of CPSF6 enhances cellular permissivity to HIV-1 infection through alternative polyadenylation.Research square · 2024Article
- Live imaging of airway epithelium reveals that mucociliary clearance modulates SARS-CoV-2 spread.Nature communications · 2024Article
- Transcription of HIV-1 at sites of intact latent provirus integration.The Journal of experimental medicine · 2024Article
- Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.PLoS pathogens · 2024Article
- Article
- Transcription of HIV-1 at sites of intact latent provirus integration.bioRxiv : the preprint server for biology · 2024Article
- Soluble CD27 is an intrathecal biomarker of T-cell-mediated lesion activity in multiple sclerosis.Journal of neuroinflammation · 2024Article
- Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Judd F HultquistDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Joseph HiattInstitute for Virology and Immunology, J. David Gladstone Institutes, San Francisco, CA, USA.
Kathrin SchumannDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Michael J McGregorDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Theodore L RothDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3970-9573
Paige HaasDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Jennifer A DoudnaInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-9161-999X
Alexander MarsonDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
Gladstone Institutes · USUniversity of California, San Francisco · USHoward Hughes Medical Institute · USNorthwestern University · USQB3 · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MX-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANKEL, ALAN D · 2007 to 2018
$48.8MProject 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KASARSKIS, ANDREW · 2015 to 2021
$46.6MThe role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MVirus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBRECHT, RANDY A. · 2013 to 2017
$26.0MMolecular Virology and Systems Biology Screening CoreP01AI090935 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI YOUNG, JOHN A T · 2010 to 2014
$20.4MDIABETES, ENDOCRINOLOGY &METABOLISM TRAINING PROGRAMT32DK007418 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 1986 to 2026
$14.3MDiscovery of novel, ubiquitin-regulated mechanisms of TB control by macrophagesR01AI120694 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S, KROGAN, NEVAN J · 2015 to 2019
$3.3MFunctional Testing of Host Genes that Control HIV Latency in Primary Immune CellsDP2DA042423 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSON, ALEXANDER · 2016 to 2016
$2.4MThe Influence of Early Integration Events on HIV Latency and Reactivation PotentialK22AI136691 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2018 to 2019
$269kEndogenous T Cell Receptor Replacement in Autoimmune DiabetesF30DK120213 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROTH, THEODORE LEE · 2018 to 2020
$64kNIAID NIH HHS K22 AI136691NIAID NIH HHS P01 AI063302NIAID NIH HHS P01 AI090935NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI120694NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI118610NIDA NIH HHS DP2 DA042423NIDDK NIH HHS F30 DK120213NIDDK NIH HHS T32 DK007418NIGMS NIH HHS P50 GM082250NIGMS NIH HHS T32 GM007618
Abstract
CRISPR-Cas9 gene-editing strategies have revolutionized our ability to engineer the human genome for robust functional interrogation of complex biological processes. We have recently adapted this technology for use in primary human CD4
Indexed as
CRISPR-Cas SystemsHigh-Throughput Screening AssaysAntibodiesAntigens, CDCD4-Positive T-LymphocytesCell NucleusClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Associated Protein 9ElectroporationGene EditingGenome, HumanHIV-1Host-Pathogen InteractionsHumansLymphocyte ActivationPrimary Cell CultureAntibodiesAntigens, CDCRISPR-Associated Protein 9RibonucleoproteinsRNA, Guide, CRISPR-Cas Systems
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.